Age, Biography and Wiki
Laura Soucek was born on 1973 in Velletri, Italy. Discover Laura Soucek's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of networth at the age of 50 years old?
| Popular As | N/A |
| Occupation | N/A |
| Age | 50 years old |
| Zodiac Sign | N/A |
| Born | , 1973 |
| Birthday | |
| Birthplace | Velletri |
| Nationality | Italy |
We recommend you to check the complete list of Famous People born on . She is a member of famous with the age 50 years old group.
Laura Soucek Height, Weight & Measurements
At 50 years old, Laura Soucek height not available right now. We will update Laura Soucek's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status | |
|---|---|
| Height | Not Available |
| Weight | Not Available |
| Body Measurements | Not Available |
| Eye Color | Not Available |
| Hair Color | Not Available |
Dating & Relationship status
She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.
| Family | |
|---|---|
| Parents | Not Available |
| Husband | Not Available |
| Sibling | Not Available |
| Children | Not Available |
Laura Soucek Net Worth
Her net worth has been growing significantly in 2022-2023. So, how much is Laura Soucek worth at the age of 50 years old? Laura Soucek’s income source is mostly from being a successful . She is from Italy. We have estimated Laura Soucek's net worth , money, salary, income, and assets.
| Net Worth in 2023 | $1 Million - $5 Million |
| Salary in 2023 | Under Review |
| Net Worth in 2022 | Pending |
| Salary in 2022 | Under Review |
| House | Not Available |
| Cars | Not Available |
| Source of Income |
Laura Soucek Social Network
Timeline
In 2019 Peptomyc was awarded the European Institute of Innovation and Technology Public Prize. She has successfully raised over €4 million in venture capital from the EIT health community. She featured in a FC Barcelona commercial to advertise the 2019/2020 season kit. The advert paid homage to people who have contributed to the community of Barcelona.
Soucek is Head of the Mouse Models of Cancer Therapies Group at VHIO and was the first woman and non-Spanish national to be appointed as Principal Investigator. She was promoted to Research Professor at ICREA in 2014. In 2014 she founded a spin-out company, Peptomyc S.L.. In 2015 she was made Associate Professor at the Autonomous University of Barcelona. Her research considers the Myc oncoprotein, a protein that cancer cells appear to depend on but had previously been considered too difficult to target. She has demonstrated that inhibition of Myc can have a therapeutic index in mouse models of cancer, causing minimal side effects in regular tissues. Soucek created Omomyc, a dominant negative form of Myc that can inhibit the oncogene without causing adverse impacts. As Omomyc is tolerated by mice and has anti-tumour activity, Soucek has been developing an efficient and safe drug version. She believes that inhibition of Myc can force the immune system to wake up, and kill cancer from the inside and outside. Peptomyc have demonstrated that Omomyc can be used against non-small-cell lung carcinoma.
Soucek was born in Velletri on the outskirts of Rome. She studied biology at the Sapienza University of Rome and graduated in 1996. After earning her bachelor's degree Soucek moved to the National Research Centre in Rome, where she started a doctorate in genetics and molecular biology. During this time she started researching novel treatments for cancer. Soucek completed her PhD in 2001 and joined the University of California, San Francisco as a postdoctoral fellow. She was appointed as an Assistant Researcher in the laboratory of Gerard Evan in 2006. She returned to Europe in 2011, joining VHIO (Vall d'Hebron Institute of Oncology).
Laura Soucek (born 1973) is a Group Leader at VHIO (the Vall d'Hebron Institute of Oncology), Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer.
